To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC80231 | Antiproliferative agent-74 |
Antiproliferative agent-74 (Compound 19a) is an anti-proliferative agent. Antiproliferative agent-74 suppresses Twist1 expression, induces weak Apoptosis. Antiproliferative agent-74 displays anti-proliferative activity against non-small cell lung cancer cells.
More description
|
|
| DC80230 | Antiparasitic agent-39 |
Antiparasitic agent-39 (Compound 14) is a selective antiparasitic agent and Deferasirox derivative. Antiparasitic agent-39 reduces the mitochondrial membrane potential. Antiparasitic agent-39 shows antiparasitic activity against T. brucei, T. gambiense, L. Mexicana, T. gondii, B. divergens, P. falciparum with EC50s of 4.2 nM, 10.4 nM, 52.0 nM, 17.0 nM, 41.2 nM, 54.8 nM, respectively.
More description
|
|
| DC80224 | anti-NSCLC agent-2 |
anti-NSCLC agent-2 (compound 6o) is a SLC7A11 and GPX4 inhibitor that reduces the expression of ferroptosis key regulators SLC7A11 and GPX4. anti-NSCLC agent-2 disrupts redox homeostasis, depletes glutathione, accumulates lipid peroxides, and induces ferroptosis in non-small cell lung cancer cells. anti-NSCLC agent-2 is applicable to research related to non-small cell lung cancer.
More description
|
|
| DC80216 | Antifungal agent 151 |
Antifungal agent 151 is a Prp8 intein inhibitor that inhibits the self-splicing process of the Prp8 intein, preventing maturation of the Prp8 protein. Antifungal agent 151 exerts in vitro antifungal activity against Cryptococcus neoformans and Cryptococcus gattii. Antifungal agent 151 can be used for the research of cryptococcus pneumonia.
More description
|
|
| DC80213 | Anticancer agent 302 |
Anticancer agent 302 (Example 1) is an anticancer agent. Anticancer agent 302 has a DC50 value of 199 nM for Cyclin E1 and an IC50 value of 133 nM for pRB. Anticancer agent 302 can be used for tumor research.
More description
|
|
| DC80204 | Antibacterial agent 313 |
Antibacterial agent 313 (Compound 20) is a broad-spectrum antibacterial agent. Antibacterial agent 313 can be used for research of bacterial infection.
More description
|
|
| DC80199 | Analgesic agent-4 |
Analgesic agent-4 is an adenosine A3AR ligand with analgesic/antinociceptive activity. Analgesic agent-4 inhibits writhing responses in mice and exhibits dose-dependent activity in the acetic acid-induced mouse writhing model. Analgesic agent-4 can be used in the research of pain-related diseases.
More description
|
|
| DC80195 | Amorphigenin |
Amorphigenin is a trothotenone compound. Amorphigenin inhibits osteoclast differentiation by suppressing the expression of c-Fos and NFATc1 in activated T cells. Amorphigenin degrades melanosome proteins by activating the AMPK-dependent autophagy pathway, but not in dependence of the mTOR pathway. Amorphigenin significantly protects bone mass and reduces bone erosion in a mouse model of inflammatory bone loss. Amorphigenin can be used to study inflammatory bone diseases, postmenopausal osteoporosis, and skin pigmentation disorders.
More description
|
|
| DC80192 | Aminobutane bisphosphonate |
Aminobutane bisphosphonate is a Trypanosoma cruzi farnesyl pyrophosphate synthase (FPPS) inhibitor with an IC50 of 30.77 μM against Trypanosoma cruzi. Aminobutane bisphosphonate inhibits proliferation of intracellular amastigote Trypanosoma cruzi and lacks activity against non-infective epimastigote forms. Aminobutane bisphosphonate reduces osteoclastic bone resorption, osteoid surface extent, and osteoclast number per mm of bone surface.Aminobutane bisphosphonate alters mineral apposition rate in intact legs, inhibits immobilization-induced bone loss, and increases trabecular bone volume in Sprague-Dawley rats. Aminobutane bisphosphonate can be used for the research of american trypanosomiasis (chagas' disease) and immobilization-related bone loss.
More description
|
|
| DC80183 | ALK-IN-24 |
ALK-IN-24 is an orally active ALK inhibitor with an IC50 value of 1.7 nM. ALK-IN-24 also inhibits insulin receptor kinase with an IC50 value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells. ALK-IN-24 inhibits ALK-driven tumor growth in xenograft mouse models. ALK-IN-24 can be used in research related to non-small cell lung cancer.
More description
|
|
| DC80182 | Alixorexton enantiomer |
Alixorexton (ALKS 2680) enantiomer is the enantiomer of Alixorexton. Alixorexton is a selective, orally active and brain-penetrant agonist for orexin-2 receptor and can be used for hypersomnias research.
More description
|
|
| DC80178 | Aldoview |
AldoView (Compound 3) is an intermediate. AldoView can be labeled with fluorine-18 to synthesize [18F]AldoView. [18F]AldoView is a highly selective aldosterone synthase PET imaging agent. AldoView can be used in imaging studies of primary aldosteronism.
More description
|
|
| DC80176 | ALC1-IN-1 |
ALC1-IN-1 (compound 1) is an ALC1 inhibitor in crystalline form that can be used in the research of cancer.
More description
|
|
| DC80171 | AKT1-IN-11 |
AKT1-IN-11, a Podophyllotoxin derivative, is a AKT1/tubulin dual inhibitor. AKT1-IN-11 down-regulates the phosphorylation level of AKT kinase in tumor cells, disrupting cell proliferation, causeing G2/M phase arrest and inducing apoptosis. AKT1-IN-11 also promotes tubulin depolymerization. AKT1-IN-11 can be used for the research of colorectal cancer.
More description
|
|
| DC80163 | AG-024104 |
AG-024104 is a CDK inhibitor with Ki values of 2.3 nM (CDK1/cyclinB), 1.8 nM (CDK2/cyclinA), and 0.67 nM (CDK4/cyclinD). AG-024104 functionally inhibits kinase activity of CDK1/cyclinB, CDK2/cyclinA, and CDK4/cyclinD. AG-024104 serves as a negative control for peripheral leukocyte toxicity studies in preclinical development.
More description
|
|
| DC80162 | AFP464 |
AFP464 (NSC710464) is a prodrug of Aminoflavone and an agonist of the aryl hydrocarbon receptor (AhR). AFP464 downregulates the expression of α6-integrin (α6-integrin), inhibits breast tumor growth, reduces the population of tumor-initiating cells, disrupts mammosphere structure, induces the formation of mucin lake clusters, triggers DNA damage, and exerts antiproliferative activity. AFP464 is rapidly converted to Aminoflavone by nonspecific esterases in plasma and cell culture media. AFP464 is applicable to research related to breast cancer.
More description
|
|
| DC80161 | Aescigenin |
Aescigenin is a triterpenoid saponin compound that can be found in Aesculus hippocastanum. Aescigenin is the main component of sodium β-aescin, a compound that has the functions of reducing tissue edema, improving microcirculation, and anti-inflammation. It can be used in research on Bell's palsy.
More description
|
|
| DC80156 | ADD-196022 |
ADD-196022 is an orally active antiepileptic and anticonvulsant agent. ADD-196022 shows ED50 values of 26.2 mg/kg and 5.79 mg/kg for intraperitoneal injection in mice and orally administration in rats. ADD-196022 can be used for the research of neurological disease.
More description
|
|
| DC80155 | ADC-VI |
ADC-VI (Compound 6) is a conjugate of a toxic molecule and a linker, in which the cytotoxin carried by CPD6 is Deruxtecan. Tricyclene is used to form an antibody-drug conjugate (ADC) by a chemical conjugation reaction through linking with an anti-FGFR2b antibody.
More description
|
|
| DC80154 | Adavosertib acid |
Adavosertib (AZD1775; MK-1775) acid (Compound 9) is a derivative of AZD1775 and can be used for the synthesis of PROTAC.
More description
|
|
| DC80151 | ACI-19278 |
ACI-19278 is a TDP-43 PET tracer with an average Kd of 25 nM. ACI-19278 only binds to pathological TDP-43 aggregates and does not cross-react with Aβ, Tau, etc. [18F]ACI-19278 successfully visualized the TDP-43 pathology in the human brain through positron emission computed tomography. ACI-19278 can be used for in vivo diagnosis of TDP-43 protein lesions.
More description
|
|
| DC80150 | ACHM-025 |
ACHM-025 is a prodrug, which is selectively activated by AKR1C3 to a nitrogen mustard DNA alkylating agent. ACHM-025 can be used for the research of cancer, such as leukemia.
More description
|
|
| DC80149 | AChE-IN-98 |
AChE-IN-98 (Compound 26) is an AChE inhitibor, with an IC50 value of 7.3 μM for ee AChE. AChE-IN-98 is also a Coumarin derivative. AChE-IN-98 can be used in the research of Alzheimer's disease.
More description
|
|
| DC80146 | AChE/MAO-B-IN-9 |
AChE/MAO-B-IN-9 (Compound E12) is an orally active, selective, reversible, non-competitive AChE and MAO-B inhibitor, with an IC50 of 0.156 μM against electric eel AChE. AChE/MAO-B-IN-9 inhibits Aβ40/42 fibril formation, promotes Aβ fibril depolymerization, and inhibits Tau protein fibril formation. AChE/MAO-B-IN-9 exerts antioxidant and neuroprotective effects, and improves scopolamine-induced memory impairment in mice. AChE/MAO-B-IN-9 can be used for the research of Alzheimer's disease.
More description
|
|
| DC80141 | ABC transporter modulator-3 |
ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC50 < 1 μM. ABCC6 modulator-3 upregulates the expression of wild-type ABCC6. ABCC6 modulator-3 is used in research on diseases associated with ABC transporter dysfunction.
More description
|
|
| DC80137 | AAK1-IN-12 |
AAK1-IN-12 (Compound 4) is a selective, orally active AAK1 inhibitor that can cross the blood-brain barrier. AAK1-IN-12 is applicable to the research of schizophrenia, Parkinson's disease, neuropathic pain and Alzheimer's disease.
More description
|
|
| DC80125 | 8-Aminoguanosine |
8-Aminoguanosine is a purine nucleoside phosphorylase inhibitor. 8-Aminoguanosine blocks purine nucleoside phosphorylation via specific binding.
More description
|
|
| DC80119 | 7.9 MAG |
7.9 MAG is a non-monoolein lipid and acts as a detergent for crystallization.
More description
|
|
| DC80118 | 6-Nitroquipazine |
6-Nitroquipazine (DU24565) is a potent and selective 5-HT transporter inhibitor, with a Ki of 0.17 nM. 6-Nitroquipazine can be used in the research of psychiatric disorders such as depression.
More description
|
|
| DC80115 | 6ECA |
6ECA is a selective TGR5 receptor activator with an EC50 of 3.44 μM. 6ECA shows no significant activity at FXR. 6ECA can be used for the study of diabesity.
More description
|
|